|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12...678910111213141516...4647» |
- ||| MK-7622 / Merck (MSD)
Enrollment closed: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - Mar 4, 2016
P2a, N=830, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting
- donepezil / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Donepezil and the Risk of Falls in Seniors With Cognitive Impairment (clinicaltrials.gov) - Mar 3, 2016
P=N/A, N=60, Active, not recruiting, Sponsor: Lawson Health Research Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=140 --> 60 | Trial primary completion date: Dec 2015 --> Jun 2016
- Trial completion, Trial primary completion date, Metastases: Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia (clinicaltrials.gov) - Mar 2, 2016
P=N/A, N=302, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting | N=140 --> 60 | Trial primary completion date: Dec 2015 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jul 2015
- | rivastigmine transdermal / Generic mfg.
Enrollment closed: RIVET: Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI (clinicaltrials.gov) - Mar 1, 2016
P3, N=138, Active, not recruiting, Sponsor: VA Office of Research and Development
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jul 2015 Recruiting --> Active, not recruiting
- BN82451 / Ipsen
Trial primary completion date: Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients (clinicaltrials.gov) - Mar 1, 2016
P2a, N=30, Recruiting, Sponsor: Ipsen
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: Imaging of Cognition, Learning, and Memory in Aging (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=550, Recruiting, Sponsor: Yaakov Stern
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Mar 2016 --> Dec 2016
- Trial primary completion date: Post-Operative Delirium in Elderly Surgical Patients (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=210, Recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: May 2016 --> Aug 2016
- Trial termination: Living With Frontotemporal Dementia (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=40, Terminated, Sponsor: National Human Genome Research Institute (NHGRI)
Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Terminated
- ||||||| galantamine extended release / Generic mfg.
Trial completion: Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease (clinicaltrials.gov) - Feb 27, 2016
P3, N=83, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Terminated Recruiting --> Completed
- |||| Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
Trial completion: Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P2, N=512, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed No longer recruiting --> Completed
- |||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
Trial completion: A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease (clinicaltrials.gov) - Feb 27, 2016
P4, N=63, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| galantamine hydrobromide / Generic mfg.
Trial completion: A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia (clinicaltrials.gov) - Feb 27, 2016
P3, N=254, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| risperidone / Generic mfg.
Trial completion: Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease (clinicaltrials.gov) - Feb 27, 2016
P3, N=473, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed No longer recruiting --> Completed
- Phase classification, Surgery: A Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia (clinicaltrials.gov) - Feb 27, 2016
P4, N=15, Completed, Sponsor: University of Pennsylvania
No longer recruiting --> Completed Phase classification: P2 --> P4
- Enrollment closed, Trial primary completion date: Music-with-Movement Intervention for People With Early Dementia and Their Families (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=134, Active, not recruiting, Sponsor: The Hong Kong Polytechnic University
Phase classification: P2 --> P4 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> May 2016
- Trial primary completion date: AZAP: Sleep Apnea in Early to Mid-Stage Alzheimer's Disease (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=100, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> May 2016 Trial primary completion date: Mar 2016 --> Jun 2017
- Trial completion, Enrollment change, Trial primary completion date: Complementary Interventions on Patients With Dementia: Comparative and Longitudinal Research (clinicaltrials.gov) - Feb 18, 2016
P=N/A, N=120, Completed, Sponsor: National Cheng-Kung University Hospital
Trial primary completion date: Mar 2016 --> Jun 2017 Recruiting --> Completed | N=200 --> 120 | Trial primary completion date: Dec 2014 --> Jul 2015
- Trial completion, Enrollment change, Trial primary completion date: CAPHA: Central Auditory Processing and the Use of Hearing Aids (clinicaltrials.gov) - Feb 18, 2016
P=N/A, N=27, Completed, Sponsor: Jong Woo Chung
Recruiting --> Completed | N=200 --> 120 | Trial primary completion date: Dec 2014 --> Jul 2015 Recruiting --> Completed | N=56 --> 27 | Trial primary completion date: Sep 2015 --> Dec 2015
- ||||||| Trintellix (vortioxetine) / Lundbeck, Takeda
Trial completion: Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder (clinicaltrials.gov) - Feb 16, 2016
P3, N=152, Completed, Sponsor: H. Lundbeck A/S
Recruiting --> Completed | N=56 --> 27 | Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Completed
- Trial primary completion date: PET Imaging in MCI Following ADT for PCa (clinicaltrials.gov) - Feb 16, 2016
P=N/A, N=12, Recruiting, Sponsor: Imperial College London
Recruiting --> Completed Trial primary completion date: Oct 2015 --> Dec 2016
- ||||| Trintellix (vortioxetine) / Lundbeck, Takeda
Enrollment closed: Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder (clinicaltrials.gov) - Feb 16, 2016
P3, N=150, Active, not recruiting, Sponsor: H. Lundbeck A/S
Trial primary completion date: Oct 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- Enrollment closed: Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=50, Active, not recruiting, Sponsor: University at Buffalo
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment change, Trial termination, Trial primary completion date: Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI (clinicaltrials.gov) - Feb 11, 2016
P=N/A, N=13, Terminated, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Recruiting --> Active, not recruiting N=50 --> 13 | Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2016 --> Feb 2016; Lack of enrollment
- haloperidol / Generic mfg.
Trial completion, Enrollment change: PE-POD: Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy (clinicaltrials.gov) - Feb 10, 2016
P4, N=152, Completed, Sponsor: Indiana University
N=50 --> 13 | Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2016 --> Feb 2016; Lack of enrollment Active, not recruiting --> Completed | N=200 --> 152
- lorazepam / Generic mfg., dexmedetomidine / Generic mfg.
Clinical: Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) (clinicaltrials.gov) - Feb 10, 2016
P4, N=49, Terminated, Sponsor: Denver Health and Hospital Authority
Active, not recruiting --> Completed | N=200 --> 152 N=150 --> 49 | Recruiting --> Terminated; DSMB recommendation for slow enrollment
- || PF-02545920 / Pfizer
Trial primary completion date: Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 (clinicaltrials.gov) - Feb 9, 2016
P2, N=260, Recruiting, Sponsor: Pfizer
N=150 --> 49 | Recruiting --> Terminated; DSMB recommendation for slow enrollment Trial primary completion date: Jun 2017 --> Sep 2017
- Trial completion, Trial primary completion date, Surgery: Cerebral Blood Flow During CPB During Cardiac Surgery and the Presence of Post op Delirium (clinicaltrials.gov) - Feb 9, 2016
P4, N=110, Completed, Sponsor: Johns Hopkins University
Trial primary completion date: Jun 2017 --> Sep 2017 Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2015
- Trial completion: FAIR-AD;PHRN08-VC / FAIR AD: FluoroAv45 Imaging Research-in Alzheimer's Disease (clinicaltrials.gov) - Feb 9, 2016
P2, N=54, Completed, Sponsor: University Hospital, Tours
Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2015 Recruiting --> Completed
- Trial initiation date, Trial primary completion date, HEOR: Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II (clinicaltrials.gov) - Feb 6, 2016
P=N/A, N=1500, Not yet recruiting, Sponsor: University of California, Los Angeles
Recruiting --> Completed Initiation date: Nov 2015 --> Jun 2018 | Trial primary completion date: Oct 2020 --> Oct 2022
- fluoxetine / Generic mfg.
Trial initiation date, Trial primary completion date: Fluoxetine Prevention Trial (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=376, Not yet recruiting, Sponsor: University of California, Los Angeles
Initiation date: Nov 2015 --> Jun 2018 | Trial primary completion date: Oct 2020 --> Oct 2022 Initiation date: Jun 2015 --> Jun 2018 | Trial primary completion date: Oct 2017 --> Oct 2020
- | blarcamesine (Anavex 2-73) / Anavex
Enrollment closed, PK/PD data: Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease (clinicaltrials.gov) - Feb 4, 2016
P2, N=32, Active, not recruiting, Sponsor: Anavex Life Sciences Corp.
Initiation date: Jun 2015 --> Jun 2018 | Trial primary completion date: Oct 2017 --> Oct 2020 Recruiting --> Active, not recruiting
- Trial primary completion date: Transcranial Direct Current Stimulation Effects in Patients With Chronic Consciousness Disorders (clinicaltrials.gov) - Feb 3, 2016
P1, N=10, Recruiting, Sponsor: University Hospital of Ferrara
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Sep 2016
- S-equol (AUS-131) / Ausio Pharma
Trial primary completion date: S-Equol in Alzheimer's Disease (SEAD) Trial (clinicaltrials.gov) - Feb 3, 2016
P1, N=15, Recruiting, Sponsor: Russell Swerdlow, MD
Trial primary completion date: Mar 2016 --> Sep 2016 Trial primary completion date: Dec 2015 --> Jul 2016
- Trial primary completion date: A Pre-Cellular Therapy Observational Study in Early Huntington's Disease (clinicaltrials.gov) - Feb 3, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: University of California, Davis
Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Dec 2015 --> Jul 2016
- | PF-05212377 / Pfizer
Enrollment change, Trial termination, Trial primary completion date: Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil (clinicaltrials.gov) - Feb 3, 2016
P2, N=186, Terminated, Sponsor: Pfizer
N=342 --> 186 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2015; The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria were met. The termination was not due to safety concerns.
- Trial primary completion date: Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI (clinicaltrials.gov) - Jan 30, 2016
P=N/A, N=50, Enrolling by invitation, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
The termination was not due to safety concerns. Trial primary completion date: Dec 2015 --> Dec 2016
- davunetide intranasal (AL-108) / Endo
Trial primary completion date: Davunetide (AL-108) in Predicted Tauopathies - Pilot Study (clinicaltrials.gov) - Jan 28, 2016
P2, N=12, Active, not recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Jul 2016
- || Trial primary completion date: Clinical Evaluation of Florbetapir F 18 (18F-AV-45) (clinicaltrials.gov) - Jan 28, 2016
P2, N=1800, Recruiting, Sponsor: Avid Radiopharmaceuticals
Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Dec 2015 --> Dec 2017
- Trial completion: Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=145, Completed, Sponsor: Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Completed
- | haloperidol / Generic mfg., ziprasidone / Generic mfg.
Trial completion: The MIND Study: Modifying the INcidence of Delirium (clinicaltrials.gov) - Jan 27, 2016
P2, N=102, Completed, Sponsor: Vanderbilt University
Recruiting --> Completed Recruiting --> Completed
- Aldurazyme (laronidase) / BioMarin, Sanofi
Trial completion, Enrollment change, Trial primary completion date: A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I (clinicaltrials.gov) - Jan 26, 2016
P=N/A, N=9, Completed, Sponsor: Patricia I. Dickson, M.D.
Recruiting --> Completed Recruiting --> Completed | N=16 --> 9 | Trial primary completion date: Dec 2014 --> Apr 2015
- Trial completion: Comparison of Hand Feeding Techniques for Persons With Dementia (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=30, Completed, Sponsor: Duke University
Recruiting --> Completed | N=16 --> 9 | Trial primary completion date: Dec 2014 --> Apr 2015 Active, not recruiting --> Completed
- Trial completion: LYLO: " The Eyes Have it " : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=83, Completed, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Recruiting --> Completed
- || atabecestat (JNJ-54861911) / J&J
Trial primary completion date: A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Jan 21, 2016
P2, N=114, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Jun 2016
- || Trial primary completion date: Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=360, Recruiting, Sponsor: Enzymotec
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Sep 2016 --> Sep 2017
- || Nuplazid (pimavanserin) / Acadia Pharma
Trial primary completion date: A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis (clinicaltrials.gov) - Jan 21, 2016
P2, N=212, Recruiting, Sponsor: ACADIA Pharmaceuticals Inc.
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Nov 2015 --> Jun 2016
- Trial completion: Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=575, Completed, Sponsor: Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Trial primary completion date: Nov 2015 --> Jun 2016 Active, not recruiting --> Completed
- Trial primary completion date: CONCEPT: Predictive Value of the Distress Thermometer as a Predictive Screening Instrument to Detect Cancer-related Cognitive Impairment in Cancer Patients (clinicaltrials.gov) - Jan 20, 2016
P=N/A, N=125, Recruiting, Sponsor: General Hospital Groeninge
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Mar 2016
- Trial primary completion date: Massage Technique for Pain, Anxiety and Delirium in SAH Patients (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=50, Recruiting, Sponsor: Sara E. Hocker, M.D
Trial primary completion date: Sep 2015 --> Mar 2016 Trial primary completion date: Sep 2016 --> Jan 2017
- Trial primary completion date: Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=150, Recruiting, Sponsor: Uniformed Services University of the Health Sciences
Trial primary completion date: Sep 2016 --> Jan 2017 Trial primary completion date: Mar 2015 --> Jun 2016